KR20140141177A - Composition for preventing, improving or treating influenza virus infection and inflammatory disease comprising salt fermented shrimp extract as an active ingredient - Google Patents

Abstract

The present invention relates to anti-influenza virus effect and anti-inflammatory effect of an extract of salted shrimps and, more specifically, provides a pharmaceutical composition and a health functional food composition containing the extract of salted shrimps as an active ingredient for preventing and treating influenza virus infection and inflammatory diseases. The present invention is very effective in preventing, alleviating, and treating influenza virus infection using the antiviral effect of the extract of salted shrimps and effectively inhibits inflammation, thereby being very effective in preventing, alleviating, and treating inflammatory diseases.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing, ameliorating or treating an influenza virus infection and an inflammatory disease comprising an extract of shrimp as an active ingredient.

The present invention relates to an anti-influenza virus effect and an anti-inflammatory effect of a shrimp extract, and more particularly to a composition for preventing, ameliorating or treating an influenza virus infection and an inflammatory disease, comprising a shrimp extract as an active ingredient.

Influenza is a virus belonging to the genus orthomyxoviridae and the influenza virus, causing respiratory diseases. The virus particles have a coating, spherical shape with a diameter of 80 to 120 nm, but they have polymorphism such as filamentous particle. The viral particles have surface antigens defined by V antigens, namely 13 kinds of red blood cell aggregates (HA) and 9 kinds of neuramidases (NA), and S antigens (antigens mainly defined as ribonucleoprotein NPs) It is divided into three types of A, B and C by the serological specificity. A type A is susceptible to the appearance of a new V antigen (HA or NA) mutant by drift or genetic segmental shift, Low levels of antibody to mutant antigens cause pandemics worldwide. The name of the isolate should be written in the order of type, natural host, subtype, isolate, segregation number, segregation year (antinuclear form of HA and NA). In addition to people, pigs, horses, and ducks are also separated. Proliferation and segment exchange occur within the animal. In type B, even when a new mutant appears, the mutation of the antigen is continuous, and the epidemic is mainly local. Type C, which proliferates into kidney and fetal cultured cells such as monkeys and cows, has one long genome and the least change in surface antigen.

The antiviruses developed so far show severe side effects and require a lot of attention to their application. In addition, development of a vaccine has a problem in that the effectiveness is low unless the virus type of the prevalent virus is matched with the virus of the vaccine.

Therefore, there is a growing need for the development of new influenza virus agents with excellent antiviral inhibition and excellent stability.

An inflammatory reaction is a defense mechanism such as an immune response that occurs in human tissues or organs for any external stimulus. However, when an excessive inflammatory response is induced, it may accompany painful diseases or harmful diseases requiring separate medication. The major chemical transfer mediators that cause the inflammatory response are amine, kinin, prostaglandin, leukotriene, and cytokine, such as histamine or serotonin.

Inflammases, on the other hand, are complex protein oligomers that are expressed in bone marrow cells and are a component of the innate immune system. Also, pattern-recognition receptors (PRRs) that are the first to respond to infection are TLPs (Toll-like receptors) and CTLs (C-type lectins) present in the cell membrane, NOD-like receptors ) And RLPs (RIG-I-like receptors) are included in the inflammases. Of these, NLRP1, which belongs to the NLRs, has been studied for many years as an inflammase, and NLRP3 and NLRC4 have also been found to belong to NLRs in a recent study. Inflammase has been reported to promote the maturation and production of pro-inflammatory cytokines, interleukin 18 (IL-18) and interleukin 1 (IL-1β).

However, traditional traditional food extracts that effectively inhibit the activity of inflammation related to inflammation and exhibit anti-inflammatory effects have not yet been studied, and development thereof is urgent.

Accordingly, the inventors of the present invention have conducted studies on anti-influenza viruses and traditional traditional food extracts excellent in anti-inflammatory activity, and found that the extract of Shrimp Shrimp is excellent in anti-influenza virus and anti-inflammatory activity and is effective for the prevention and treatment of influenza virus infection and inflammatory diseases And completed the present invention.

Accordingly, it is an object of the present invention to provide a pharmaceutical composition for preventing and treating influenza virus infection comprising an extract of shrimp as an active ingredient.

Yet another object of the present invention is to provide a health functional food composition for preventing and improving influenza virus infection comprising an extract of Shrimp Saliva as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising an extract of Shrimp Saw as an active ingredient.

Another object of the present invention is to provide a health functional food composition for preventing and ameliorating inflammatory diseases, which comprises an extract of Shrimp Saliva as an active ingredient.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing and treating influenza virus infection comprising an extract of a shrimp as an active ingredient.

In order to accomplish another object of the present invention, the present invention provides a health functional food composition for preventing and improving influenza virus infection comprising an extract of Shrimp Saliva as an active ingredient.

In order to achieve the other object of the present invention, the present invention provides a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising an extract of Shrimp Saliva as an active ingredient.

In order to accomplish another object of the present invention, the present invention provides a health functional food composition for preventing and improving inflammatory diseases, which comprises an extract of Shrimp Saliva as an active ingredient.

Hereinafter, the present invention will be described in detail.

The pharmaceutical composition of the present invention is effective for the prevention and treatment of influenza virus infection and inflammatory diseases by containing the shrimp extract as an active ingredient.

Salted salted shrimps are salted salted fish. Salted shrimps are most commonly consumed with fermented anchovies in the fermented seafood, and are used as ingredients to flavor various Korean dishes, especially kimchi, when flavored. The shrimp sauce is so low in fat that it tastes light. Unlike ordinary shrimp, it is small in size and thin in shell. There are middle - shrimp, salted fish, and insects in jumbo shrimp, and they are immersed in freshwater prawns according to their localities. Salted shrimps contain strong digestive elements in the gut, which easily breaks down meat quality. During the fermentation of salted shrimps, the content of betamines increases, and the chitin present in the shrimp shell is partially degraded into chitin oligosaccharides. Chitin oligosaccharides are known to increase immunity, inhibit cancer and prevent metastasis. Betaine has also been used as a medicinal product to control the acidity of stomach juices and has been reported to have a beneficial effect in improving hepatic function disorders caused by hyperlipidemia, obesity, fatty liver and alcohol.

The shrimp extract of the present invention can be extracted by a known natural substance extraction method and is preferably extracted with one or more solvents selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, and subcritical or supercritical fluids. , The organic solvent having 1 to 6 carbon atoms may be selected from the group consisting of alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride methylene chloride, hexane, cyclohexane, and petroleum ether.

The extraction temperature of the extract of the present invention is not particularly limited and may be, for example, Lt; 0 > C, preferably from room temperature to 50 < 0 > C. The extraction time of the extract of the present invention is not particularly limited, and may be, for example, 1 hour to 10 days, preferably 2 hours to 6 hours.

The extract of the present invention can be extracted by a known natural substance extraction method. For example, it can be extracted by cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, or heat extraction, preferably by hot water extraction or reflux cooling extraction. The extraction can be performed once to 10 times, preferably twice To 7 times.

The extract of the present invention can be used as a liquid phase by filtration, and can be solidified through a drying process such as spray drying or lyophilization. More preferably, the dextrin can be mixed and dried before spray drying or freeze-drying.

Influenza is a virus belonging to the genus orthomyxoviridae and the influenza virus, causing respiratory diseases. Influenza virus particles have a coating and spherical shape with a diameter of 80 to 120 nm, but they have polymorphism such as filamentous particle. The viral particles have surface antigens defined by V antigens, namely 13 kinds of red blood cell aggregates (HA) and 9 kinds of neuramidases (NA), and S antigens (antigens mainly defined as ribonucleoprotein NPs) It is divided into three types of A, B and C by the serological specificity. A type A is susceptible to the appearance of a new V antigen (HA or NA) mutant by drift or genetic segmental shift, Low levels of antibody to mutant antigens cause pandemics worldwide. In addition to humans, pigs, horses, and ducks are also isolated, and proliferation and segment exchange occur within the organism. In type B, even when a new mutant appears, the mutation of the antigen is continuous, and the epidemic is mainly local. Type C, which proliferates into kidney and fetal cultured cells such as monkeys and cows, has one long genome and the least change in surface antigen.

The influenza virus of the present invention may be preferably an influenza A virus, more preferably a H1N1 virus which is one of the subtypes of influenza A virus.

The disease caused by the influenza virus infection of the present invention may be influenza symptoms such as flu, cold, sore throat, bronchitis, pneumonia, fever, chills, headache and cough, sore throat, runny nose, shortness of breath, muscular pain, joint pain, fatigue, But can be preferably flu, cold, sore throat, bronchitis and pneumonia.

In one embodiment of the present invention, the inhibitory effect of influenza virus on the concentration of the shrimp extract was tested with cytotoxicity. As a result, the shrimp extract had low cytotoxicity at a concentration of less than 3.3333 mg / mL, and the effect of anti-influenza virus was excellent at a concentration of 0.0046 mg / mL (see FIG. 1).

Meanwhile, the extract of the present invention has an excellent effect for preventing, improving or treating an inflammatory disease. Such inflammatory diseases include, but are not limited to, inflammatory bowel disease, peritonitis, osteomyelitis, cachexia, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, acute bronchitis, Inflammatory bowel disease, inflammatory bowel disease, chronic bronchitis, acute bronchiolitis, chronic bronchitis, osteoarthritis, gout, spondyloarthropathies, ankylosing spondylitis, lager syndrome, psoriatic arthropathy, intestinal disease, spondyloarthropathies, Arthritis associated with " vasculitis syndrome ", nodular polyarteritis, irritable vasculitis, Lou Gehrig's granulomatosis, rheumatoid multiple myalgia, arthritic cells, arthritis, arthritis, osteoarthritis, osteoarthritis, osteoarthritis, osteoarthritis, Arthritis, Calcium Crystallization Arthropathy, Pseudo-gout, Non-articular rheumatism, (Also called " charcot joint "), hemarthrosis, Henoch-Schönlein purpura, hypertrophic osteoarthritis, hypertrophic osteoarthritis, osteoarthritis, Atherosclerosis, septicemia, septicemia, septicemia, septicemia, scoliosis, hemochromatosis, hemochromatosis, hyperlipidemia, hypogammaglobulinemia, familial Mediterranean fever, Behcet's disease, systemic lupus erythematosus, Acute respiratory distress syndrome, multiple organ failure, chronic obstructive pulmonary disease, rheumatoid arthritis, acute lung injury, broncho-pulmonary dysplasia, Type 2 diabetes, arteriosclerosis, Alzheimer ' s dementia, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, , Neonatal mutisystem inflammatory disease, chronic infantile neurologic cutaneous articular syndrome, adult-onset still's disease, contact dermatitis, hydatidiform mole ), PAPA syndrome (pyoderma gangrenosum, and acne), hyperimmunoglobulin d syndrome and cryopyrin-associated periodic syndromes.

In one embodiment of the present invention, in order to test the anti-inflammatory effect of the shrimp extract, the inhibition of the inflammatory mediator protein inflamase activity was tested. As a result of treating infrahamese activity inhibition by treatment with ATP which is an active agent of inflammase, the ability of inhibiting effective inflammase activity was observed at a concentration of 0.625 mg / mL or more of the shrimp extract (Fig. 3 4 and Fig. 5)

Inflammase is present in the cytoplasm of myeloid cells and is a protein complex composed of innate immune receptors (NOD-like receptor), adapter protein (ASC) and caspase-1. It is a precursor of cytokine -Interleukin-1? (Pro-IL-1?) Into the active form IL-1? (P17). The shrimp extract of the present invention can effectively control the secretion amount of the inflammatory cytokine IL-1 beta by inhibiting the activity of such inflammase, and thus has an excellent effect for the prevention and treatment of inflammatory diseases.

Therefore, the pharmaceutical composition of the present invention comprising the extract of Shrimp Sake as an active ingredient is effective for prevention and treatment of diseases caused by influenza virus infection, and is also effective for prevention and treatment of inflammatory diseases caused by inflammation.

The pharmaceutical compositions according to the present invention may further comprise a pharmaceutically effective amount of a salted salted extract alone or in combination with one or more pharmaceutically acceptable carriers, excipients or diluents. The term "pharmaceutically acceptable" as used herein means a non-toxic composition which is physiologically acceptable and which, when administered to humans, does not inhibit the action of the active ingredient and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, .

Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The pharmaceutical composition may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifier, and an antiseptic agent.

The term "pharmaceutically effective amount" as used herein refers to an amount that shows a reaction more than the negative control, and preferably refers to an amount sufficient to exhibit the effect of influenza virus infection and prevention and treatment of inflammatory diseases. The pharmaceutically effective amount of the shrimp extract according to the present invention is 0.01 to 100 mg / day / kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on various factors such as the type and severity of the disease, the age, body weight, health condition, sex, administration route and treatment period of the patient.

In addition, the pharmaceutical composition of the present invention may be formulated using methods known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal. The formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatine capsules, sterile injectable solutions, sterile powders.

The administration route of the composition of the present invention is not limited thereto, but it can be administered orally or parenterally. Parenteral routes of administration include, for example, various routes such as transdermal, nasal, peritoneal, muscular, subcutaneous or intravenous.

The pharmaceutical composition of the present invention may be administered in combination with a known compound having an effect of preventing and treating diseases caused by inflammation and influenza virus infection.

The present invention also provides a health functional food composition for preventing and ameliorating influenza virus infection comprising an extract of shrimp as an active ingredient.

The health functional food composition of the present invention is effective for prevention and improvement of influenza virus infection by containing the shrimp extract as an active ingredient.

The present invention also provides a health functional food composition for preventing and ameliorating inflammatory diseases comprising an extract of Shrimp Saliva as an active ingredient.

The health functional food composition of the present invention is effective for prevention and improvement of inflammatory diseases by containing shrimp extract as an active ingredient.

The term " health functional food "of the present invention means a food prepared and processed by using a raw material or ingredient having useful functionality in the human body according to Law No. 6727 on health functional foods, and" And function of the nutrient for the purpose of obtaining a beneficial effect in health use such as controlling the nutrient or physiological action.

The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, the health food may be prepared by ingesting the lobster extract itself in the form of tea, juice and drink, or ingested by granulating, encapsulating and pulverizing. In addition, the composition of the present invention can be prepared by mixing the extract of the present invention with known active ingredients known to be effective for preventing or ameliorating diseases or conditions caused by influenza virus infection and inflammatory diseases.

Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (e.g., canned fruits, bottled, jam, maalmalade, etc.), fish, meat and processed foods such as ham, Etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, Retort food, frozen food, various seasonings (eg, soybean paste, soy sauce, sauce, etc.), and the like. In addition, in order to use the extract of the present invention as a food additive, it may be used in the form of powder or concentrate.

The preferred content of the shrimp extract in the food composition of the present invention is 0.001 to 50% by weight, preferably 0.1 to 30% by weight, based on the total weight of the food composition.

The present invention relates to an anti-influenza virus effect and an anti-inflammatory effect of a shrimp extract, and more particularly, to a composition for preventing and treating an influenza virus infection and an inflammatory disease comprising an extract of a shrimp as an active ingredient. The present invention is effective in preventing, ameliorating or treating an influenza virus infection by using an antiviral effect of a shrimp extract, and is effective in preventing, ameliorating or treating an inflammatory disease by inhibiting inflammation.

Fig. 1 shows the effect of inhibiting influenza by the concentration of shrimp extract. (Horizontal axis: concentration of salted salted extract (mg / mL), vertical axis: cell activity (OD), con -: no influenza virus, con +: influenza virus, cytotoxic: cytotoxic, antiviral activity of influenza inhibitor)
Fig. 2 shows the effect of inhibiting influenza by the concentration of Tamiflu. (Influenza-inhibiting effect), (cytotoxic: cytotoxic effect of Tamiflu), (concentration of influenza virus)
Fig. 3 shows the effect of inhibiting the inflammation of the shrimp extract. The inhibitory effect of the inflammase was detected by western blot in the amount of active IL-1β released into the cell culture. (Sup.: Cell culture, Lys.: Intracellular protein extract, IL-1β: active cytokine, pro-IL-1β: precursor cytokine.) Here, LPS-> Non is a negative control without ATP treatment it means.
4 is a graph showing the quantification of the amount of IL-1? (Active form) detected in the cell culture supernatant according to the concentration of the shrimp extract. The black bars in the graph mean ATP treatment alone, while the white bars indicate that ATP and shrimp extract were combined. (Width: concentration of salted salted extract (mg / ml), height: relative intensity (%))
FIG. 5 is a graph showing the quantification of the amount of IL-1? (Active form) detected in the cell culture supernatant according to the concentration of the shrimp extract. The black bars in the graph mean ATP treatment alone, while the white bars indicate that ATP and shrimp extract were combined. (Width: concentration of salted salted extract (mg / ml), height: relative intensity (%))

Hereinafter, the present invention will be described in detail.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

≪ Example 1 >

Preparation of shrimp extract

The raw material of the shrimp used as the sample was 87% of the domestic shrimp and 13% of the domestic refined salt as raw materials, and it was purchased from Chinin Food Co., Ltd. (549-2, Ongam-ri, Gwangcheon- It is made by the month and it is refrigerated at 0-10 ℃. And KOSHIN cave food No. 155, respectively.

Add 1 L of water to 1 kg of salted shrimp, mix with a mixer, mix, add 2 L of ethanol (99.99% v / v), mix well and extract overnight at room temperature. The filtrate was collected using a coarse filter paper (Advantec No. 1), and the filtrate was collected and concentrated under reduced pressure at 55 to 65 ° C. When the ethanol was completely removed, the concentrate was collected and filtered through a micro filter paper (Advantec No. 2).

The filtrate was adsorbed on 500g of sea sand (30 ~ 50 mesh) to about 100g (solids content 5 ~ 50% w / w) of concentrated ethanol and the water was completely removed by decompression at 50 ~ 65 ℃. After the homogeneous crushing of the seaweed adsorbed on the concentrate, about 2 L of ethanol (99.99% v / v) was added and the mixture was slowly stirred at 50 to 65 ° C for secondary extraction. In this process, only ethanol-soluble components were extracted, and components such as sodium chloride, which only dissolve in water and do not dissolve in ethanol, and those that solidify in ethanol, such as dietary fiber and protein, were not extracted. After the second extraction, the filtrate was removed by filtration, and the filtrate was collected. The filtrate was mixed with an equal amount of water, and the filtrate was concentrated under reduced pressure at 55-65 ° C to remove ethanol. The ethanol was removed and the remaining water was concentrated to prepare a second extract.

The pH of the second extract was adjusted to pH 7.4 using 1.0 or 0.1 mol / L sodium hydroxide solution (NaOH), and the solids content was measured by the evaporation drying method at 105 ° C. The final solids content was adjusted to 100 mg / .

≪ Example 2 >

Cytotoxicity and Influenza Virus Inhibitory Effect of Shrimp Extract

≪ Example 2-1 >

Madin-Darby canine kidney epithelial cell (MDCK Line) was used as a cell line. 96-well plate culture medium to each well of a (cell growth media; MEM + 10 % FSB + 100 U / mL penicillin + 0.1 mg / mL streptomycin) into the 100 μL, a cell line ^{(MDCK cell) 1.5 x 10 5} cells / ml And the cell density (cell confluence) was 70% -80%.

<Example 2-1> Cytotoxicity evaluation

In order to evaluate cytotoxicity, the shrimp extract was treated at concentrations ranging from 10.0000 mg / mL to 0.0015 mg / mL, followed by incubation at 37 ° C for 48 hours with 5% CO ₂ The cell line was cultured with an incubator, and the surviving cell line was stained with MTT method and absorbance was measured.

The cytotoxicity evaluation results of the shrimp extract are shown in Fig. When the extract was added to the cell line, the absorbance gradually increased as the solids content of the shrimp extract was diluted and decreased. Shrimp extract showed low cytotoxicity at concentrations below 3.3333 mg / mL of solids.

Example 2-2 Influenza Virus Inhibitory Effect

To examine the anti-influenza effect, the shrimp extract was treated at concentrations ranging from 10.0000 mg / mL to 0.0015 mg / mL and H1N1 (PR8) influenza virus was inoculated as shown in Fig. As a control experiment, tamiflu (TAMIFLU, oseltamivir phosphate) was treated at different concentrations and inoculated with influenza virus as shown in Fig. The cells were cultured in a 5% CO ₂ incubator at 37 ° C for 48 hours, and the surviving cell line was stained with MTT method and absorbance was measured.

The anti-influenza effect of the shrimp extract is shown in Fig. At the concentration of 0.0046 mg / mL, the absorbance reached a maximum value of 0.8, indicating the maximum inhibition of influenza virus. In comparison with the control experiment in which the Tamiflu treated with [Fig. 2], the absorbance of the live cell line at the concentration of 0.0046 mg / mL was 1.1, and about 73% of the efficacy of Tamiflu (the absorbance of the shrimp extract was 0.8 / The absorbance of Tamiflu 1.1).

< Example  3>

Antiinflammatory effect of shrimp extract

Example  3-1. mouse Bone marrow origin  Macrophage isolation and culture

After euthanating the mouse (C57BL6, orient bio), the femur and tibia are separated. Separate bone is pierced and bone marrow is extracted with a syringe. RBC lysis buffer (intron biotech, Seoul, Korea) was added to the extracted bone marrow to destroy red blood cells. Bone marrow cells from which erythrocytes were removed were differentiated into macrophages for 1 week in DMEM (10% FBS) supplemented with approximately 30% of L929 (Korea Cell Line Bank) culture. Macrophages (10 ⁶ cells) were post-cultured on a 12-well plate and inflammation activity experiments were performed.

< Example  3-2> Inflammase  Activity evaluation

In order to observe the inhibitory effect of the inflammatory mediator protein, 2mM of an artificial influenza (NLRP3 inflammatory) activator, adenosine triphosphate (ATP, invitogen, Sandiego, CA, USA) was injected into bone marrow derived macrophages BMDM), and then the amount of IL-1β produced by the infected smell of shrimp extract was measured and evaluated.

IL-1β precursor (pro-IL-1β) was produced by treating LPS (10 ug / ml, Sigma-aldrich) for 3 hours. Thereafter, RMPI (Wellgene, Seoul, Korea) is treated with the active drug, ATP (2 mM) and salted salted extract, for 1 hour at the same time, and the culture solution is collected. In addition, intracellular proteins were extracted.

The collected cultures and intracellular proteins were electrophoresed on PAGE-gel (16% or 10%). The protein is then transferred to a PVDF membrane (Pall Corporation, USA). Membranes were incubated with 3% skimmed milk powder in a solution containing antibody (IL-1β [R & D system] or Actin [Santa Cruz biotech], 1: 1000) overnight. The next day, the cells were washed with PBS and cultured for 3 hours in a secondary antibody (Santa Cruz biotech, 1: 10,000) with HRP. After completion of the reaction, the membrane was washed with PBS and reacted with an ECL solution (Philekore), and analyzed using a luminescence assay (Ez-Capture, Atto).

As a result, there was no activity of infectious mushroom extract in its own, and no macrophage toxicity was observed in the total concentration of the shrimp extract used in the experiment. As shown in [Figure 2], [Figure 3] and [Figure 4], effective inflammase inhibitory potency was observed at concentrations greater than 0.625 mg / ml.

Accordingly, the present invention relates to an anti-influenza virus effect and an anti-inflammatory effect of a shrimp extract, and more particularly, to a pharmaceutical composition for preventing and treating an influenza virus infection and an inflammatory disease, Lt; / RTI &gt; The present invention has an excellent effect in preventing, ameliorating or treating influenza virus infection by using the antiviral effect of the shrimp extract, and has an excellent effect in effectively preventing inflammation and preventing, improving or treating an inflammatory disease, high.

Claims (7)

A pharmaceutical composition for preventing and treating influenza virus infection, comprising an extract of Shrimp Saw as an active ingredient.
A health functional food composition for preventing and improving influenza virus infection comprising an extract of shrimp as an active ingredient.
3. The composition according to claim 1 or 2, wherein the influenza virus is the H1N1 virus.
3. The composition according to claim 1 or 2, wherein the disease caused by the influenza virus infection is influenza, cold, sore throat, bronchitis and pneumonia.
A pharmaceutical composition for preventing and treating inflammatory diseases, which comprises an extract of Shrimp Sauce as an active ingredient.
A health functional food composition for preventing and improving inflammatory diseases, which comprises an extract of Shrimp Saw as an active ingredient.
7. The method of claim 5 or 6, wherein the inflammatory disease is selected from the group consisting of inflammatory bowel disease, peritonitis, osteomyelitis, cachexia, pancreatitis, trauma induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, acute bronchitis, chronic bronchitis, Chronic bronchitis, osteoarthritis, gout, spondyloarthropathies, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, intestinal disease, spondyloarthropathies, ankylosing spondylitis, rheumatoid arthritis, infectious arthritis, post-infectious arthritis, gonocoele arthritis Arthritis associated with vasculitis syndrome, nodular polyarteritis, irritable vasculitis, Lou Gehrig's granulomatosis, rheumatoid multiple myalgia, arthropathic arthritis, calcium crystal deposition Arthropathy, caustic gout, non-articular rheumatism, bursitis, hay fever, suppurative (tennis elbow), nerves A neuropathic joint disease (also referred to as a &quot; charcot joint &quot;), hemarthrosic, Henoch-Schlenstein purpura, hypertrophic osteoarthritis, multisymmetric hematopoietic system, scoliosis, hemochromatosis, hemochromatosis , Hyperlipoproteinemia, hypogammaglobulinemia, familial Mediterranean fever, Behcet's disease, systemic lupus erythematosus, recurrent fever, multiple sclerosis, sepsis, septic shock, acute respiratory distress syndrome, multiple organ failure, chronic obstructive Chronic obstructive pulmonary disease, rheumatoid arthritis, acute lung injury, broncho-pulmonary dysplasia, type 2 diabetes, atherosclerosis, Alzheimer &apos; s dementia, family Muckle-Wells syndrome, neonatal mutisystem in (Muckle-Wells &apos; s syndrome), &lt; RTI ID = 0.0 & flammatory disease, chronic infantile neurologic cutaneous articular syndrome, adult-onset still's disease, contact dermatitis, hydatidiform mole, PAPA syndrome (syndrome of pyogenic arthritis pyoderma gangrenosum, and acne), hyperimmunoglobulin d syndrome, and cryopyrin-associated periodic syndromes. The composition of claim 1,

Images